Dossier

Les soins de support en 2016

Mis en ligne le 31/03/2017

Auteurs : F. Scotté, P. Leroy, C. Thibault

Lire l'article complet (pdf / 182,44 Ko)

Les soins de support et les traitements qui y sont rattachés font toujours l'objet d'une activité scientifique riche. Un retour bibliographique sur l'année 2016 apporte des enseignements autour des mises à jour de recommandations, telles que celles traitant des antiémétiques ou de la prise en charge de la douleur cancéreuse.

Le développement des thérapeutiques innovantes impose une vigilance sur les tolérances et les solutions offertes pour limiter et prévenir les toxicités induites. L'anémie et la neutropénie restent d'actualité. Le droit à l'oubli des patients en rémission d'un cancer fait également partie de cette thématique, puisque directement rattaché à la phase après-cancer.

Références

1. Champiat S, Lambotte O, Barreau E et al. Management of immune checkpoint blockade dysimmune toxicities: a ­collaborative position paper. Ann Oncol 2016;27(4):559-74.

2. Murphy MF, Dumont LJ, Greinacher A; BEST Collaborative. Interference of new drugs with compatibility testing for blood transfusion. N Engl J Med 2016;375(3):295-6.

3. Spain L, Walls G, Julve M et al. Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. Ann Oncol 2016. [Epub ahead of print]

4. Wick W, Hertenstein A, Platten M. Neurological sequelae of cancer immunotherapies and targeted therapies. Lancet Oncol 2016;17(12):e529-41.

5. Weinstein C, Jordan K, Green SA et al. Single-dose fosaprepitant for the prevention of chemo­therapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial. Ann Oncol 2016;27(1):172-8.

6. Navari RM, Qin R, Ruddy KJ et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med 2016;375(2):134-42.

7. Roila F, Molassiotis A, Herrstedt J et al.; participants of the MASCC/ESMO Consensus Conference Copenhagen 2015. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 2016;27(Suppl. 5):
v119-33.

8. Zimmerman C, Atherton PJ, Pachman D et al. MC11C4: a pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy. Support Care Cancer 2016;24(3):1071-8.

9. Hsieh YL, Fan YC, Yang CC. Low-level laser therapy alleviates mechanical and cold allodynia induced by oxaliplatin administration in rats. Support Care Cancer 2016;24(1):233-42.

10. Hershman DL, Till C, Wright JD et al. Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants 65 years or older in Southwest Oncology Group Clinical Trial. J Clin Oncol 2016;34(25):3014-22.

11. Lipton A, Fizazi K, Stopeck AT et al. Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics. Eur J Cancer 2016;53:75-83.

12. Kaymakcalan MD, Xie W, Albiges L et al. Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: results from the International Metastatic Renal Cell Carci­noma Database Consortium. Cancer 2016;122(3):411-9.

13. Hurria A, Mohile S, Gajra A et al. Validation of a prediction tool for chemotherapy toxicity in older adults with cancer. J Clin Oncol 2016;34(20):2366-71.

14. Basch E, Deal AM, Kris MG et al. Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J Clin Oncol 2016;34(6):557-65.

15. Leyland-Jones B, Bondarenko I, Nemsadze G et al. A rando­mized, open-label, multicenter, phase III study of epoetin alfa versus best standard of care in anemic patients with metastatic breast cancer receiving standard chemotherapy. J Clin Oncol 2016;34(11):1197-207.

16. Laï-Tiong F, Brami C, Dubroeucq O et al. Management of anemia and iron deficiency in a cancer center in France. Support Care Cancer 2016;24(3):1091-6.

17. Aapro MS, Bohlius J, Cameron DA et al.; European Organisation for Research and Treatment of Cancer. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemo­therapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011;47(1):8-32.

18. Recommandations NCCN sur la neutropénie. Disponibles sur www.nccn.org/store/login/login.aspx?­ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/myeloid_growth.pdf

19. Weycker D, Li X, Figueredo J et al. Risk of chemo­therapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter? Support Care Cancer 2016;24(5):2309-16.

20. Bondarenko IM, Bias P, Buchner A. Incidence of bone pain in patients with breast cancer treated with lipegfilgrastim or pegfilgrastim: an integrated analysis from phase II and III studies. Support Care Cancer 2016;24(1):267-73.

21. Aapro M, Ludwig H, Bokemeyer C et al. Predictive modeling of the outcomes of chemotherapy induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (­MONITOR-GCSF study). Ann Oncol 2016;27(11):2039-45.

22. Aapro MS, Bohlius J, Cameron DA et al. European Organisation for Research and Treatment of Cancer. 2010 update of EORTC guidelines for the use of granulocyte-­colony stimulating factor to reduce the incidence of chemo­therapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011;47(1):8-32.

23. Paice JA, Portenoy R, Lacchetti C et al. Management of chronic pain in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2016;34(27):3325-45.

24. Frieden TH, Houry D. Reducing the risk of relief – The CDC Opioid-Prescribing Guideline. N Engl J Med 2016;374(16):1501-4.

25. Tanday S. Duloxetine lessens joint pain in early-stage breast cancer. Lancet Oncol 2017;18(1):e10.

26. Tao WW, Jiang H, Tao XM et al. Effects of acupuncture, tuina, Tai Chi, Qigong, and traditional Chinese medicine five-element music therapy on symptom management and quality of life for cancer patients: a meta-analysis. J Pain Symptom Manage 2016;51(4):728-47.

27. Lesi G, Razzini G, Musti MA et al. Acupuncture as an integrative approach for the treatment of hot flashes in women with breast cancer: a prospective multicenter randomized controlled trial (AcCliMaT). J Clin Oncol 2016;34(15):1795-802.

28. Temel JS, Abernethy AP, Currow DC et al. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol 2016;17(4):519-31.

29. Dumas A, De Vathaire F, Vassal G. Access to loan-­related insurance for French cancer survivors. Lancet Oncol 2016;17(10):1354-6.

30. AERAS. Le droit à l’oubli. Disponible sur : www.aeras-infos.fr/cms/sites/aeras/accueil/aeras-en-pratique/les-points-cles/le-droit-a-loubli.html

Liens d'interêts

F. Scotté déclare avoir des liens d’intérêts avec Roche, Vifor, MSD, Teva, Norgine, ProStrakan, Leo Pharma, Janssen, Hospira, Boehringer Ingelheim, Sanofi, Amgen, Pierre Fabre Oncologie, Tessaro.

P. Leroy déclare ne pas avoir de liens d’intérêts.

C. Thibault déclare avoir des liens d’intérêts avec Roche.

auteurs
Dr Florian SCOTTÉ

Médecin, Oncologie, Institut Gustave-Roussy, Villejuif, France

Contributions et liens d’intérêts
Dr Pauline LEROY

Médecin, Médecine générale, Hôpital Foch, Suresnes, France

Contributions et liens d’intérêts
Dr Constance THIBAULT

Médecin, Oncologie, Hôpital européen Georges-Pompidou, Paris, France

Contributions et liens d’intérêts
centre(s) d’intérêt
Oncologie générale
thématique(s)
Soins oncologiques de support
Mots-clés